Prosecution Insights
Prosecution Insights
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (60%) |
| No statute on record | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PIHONAK, SARAH | 1 | 60.9% | +43.4% |
| MOU, LIYUAN | 1 | 43.2% | +58.1% |
| BEANE, RANDALL L | 1 | 32.5% | +37.8% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 56.8% | +41.6% |
| VALENROD, YEVGENY | 1 | 72.6% | +25.4% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18034411 | RIFAXIMIN LIQUID FORMULATIONS FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | MOU, LIYUAN | 77d overdue |
| 18186292 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | BEANE, RANDALL L | 73d overdue |
| 17913844 | SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY | ROBINSON, MIKHAIL O'DONNEL | 73d overdue |
| 18276120 | AMISELIMOD FOR PREVENTING, TREATING OR AMELIORATING ULCERATIVE COLITIS | PIHONAK, SARAH | 22d overdue |
| 17747938 | POLYMERIC EMULSION DELIVERY SYSTEMS | VALENROD, YEVGENY | 43d |
| Art Unit | Apps |
|---|---|
| 1627 | 2 |
| 1628 | 2 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18276120 | AMISELIMOD FOR PREVENTING, TREATING OR AMELIORATING ULCERATIVE COLITIS | PIHONAK, SARAH | 1627 | §103 | Non-Final OA | 22d overdue | Pending | Aug 07, 2023 |
| 18034411 | RIFAXIMIN LIQUID FORMULATIONS FOR USE IN THE TREATMENT OF SICKLE CELL DISEASE | MOU, LIYUAN | 1628 | Other | Non-Final OA | 77d overdue | Pending | Apr 28, 2023 |
| 18186292 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | BEANE, RANDALL L | 1654 | §103 | Non-Final OA | 73d overdue | Pending | Mar 20, 2023 |
| 17913844 | SOLID DISPERSIONS OF RIFAXIMIN FOR THE TREATMENT OF OVERT HEPATIC ENCEPHALOPATHY | ROBINSON, MIKHAIL O'DONNEL | 1627 | §103 | Final Rejection | 73d overdue | Pending | Sep 23, 2022 |
| 17747938 | POLYMERIC EMULSION DELIVERY SYSTEMS | VALENROD, YEVGENY | 1628 | Other | Final Rejection | 43d | Pending | May 18, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial